Treace Medical Concepts (TMCI) to Release Earnings on Thursday

Key Points

• Treace Medical Concepts is set to release its Q2 2025 earnings on Thursday, August 7th, with analysts projecting a loss of ($0.28) per share on revenues of $47.08 million.
• In its last quarterly report, the company reported revenue of $52.57 million, surpassing analyst expectations, while posting a loss of ($0.25) per share, beating estimates by $0.06.
• Institutional investors hold 84.08% of Treace Medical Concepts' stock, with Millennium Management recently increasing its stake by 35.3% in the first quarter.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) is anticipated to release its Q2 2025 earnings data after the market closes on Thursday, August 7th. Analysts expect Treace Medical Concepts to post earnings of ($0.28) per share and revenue of $47.08 million for the quarter. Treace Medical Concepts has set its FY 2025 guidance at EPS.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.06. The business had revenue of $52.57 million for the quarter, compared to the consensus estimate of $52.07 million. Treace Medical Concepts had a negative return on equity of 48.69% and a negative net margin of 25.14%. The business's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.30) earnings per share. On average, analysts expect Treace Medical Concepts to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Treace Medical Concepts Price Performance

Shares of NASDAQ TMCI traded down $0.03 during mid-day trading on Friday, reaching $5.34. The company's stock had a trading volume of 365,581 shares, compared to its average volume of 240,226. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.50 and a quick ratio of 3.36. Treace Medical Concepts has a 52 week low of $4.54 and a 52 week high of $10.79. The stock has a fifty day moving average of $5.83 and a two-hundred day moving average of $7.39. The firm has a market capitalization of $335.83 million, a PE ratio of -6.28 and a beta of 0.68.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Truist Financial dropped their price target on Treace Medical Concepts from $9.50 to $8.00 and set a "hold" rating for the company in a research note on Friday, April 11th. UBS Group dropped their target price on shares of Treace Medical Concepts from $10.00 to $8.60 and set a "neutral" rating for the company in a research report on Friday, May 9th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Treace Medical Concepts currently has a consensus rating of "Hold" and an average price target of $10.52.

Hedge Funds Weigh In On Treace Medical Concepts

An institutional investor recently bought a new position in Treace Medical Concepts stock. AQR Capital Management LLC bought a new stake in shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 58,523 shares of the company's stock, valued at approximately $491,000. AQR Capital Management LLC owned about 0.09% of Treace Medical Concepts as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 84.08% of the company's stock.

About Treace Medical Concepts

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.